About Us
CancerIQ helps providers use genetic information to predict, pre-empt, and prevent disease - starting with cancer. By making is easier to identify patients at risk, offer a genetic evaluation at point of care, and design a tailored cancer prevention plan - we can help healthcare systems get ahead of this costly and emotionally devastating disease.

Why Work with Us?
We have quietly built a market-leading product that patients, providers, and healthcare executives all love. With new funding and new strategic partners, we're on pace for rapid growth. We're a team of clever, scrappy, and mission-driven individuals making a huge impact in cancer prevention - so if you're passionate about healthcare - join our team.

1776 Ventures

Rock Health Capital

HealthX Ventures

Impact Engine

Lightbank

OSF Ventures

McKesson Ventures

Merck Global Health Innovation Fund

Amgen Ventures

CancerIQ

CancerIQ believes that everyone, regardless of where they live, deserves the chance to prevent, detect, and treat cancer effectively. Our message this World Cancer Day is clear: the fight against cancer requires more than just digital innovation; it demands equitable approaches to implementation. 

Our impact goes beyond metrics, representing lives saved, families preserved, and communities strengthened. Help us make our mission a reality by joining our team. https://bit.ly/3Ovpzbl

#WorldCancerDay #CloseTheCareGap #AheadOfCancer #PrecisionPrevention

We're incredibly proud to kick off Cancer Prevention Awareness Month with the news that industry leader Diedre Mavin Senatra has joined the team as SVP, Commercial Strategy! She joins CancerIQ at a critical time, as providers must update protocols to meet expanded industry guidelines for cancer risk assessment and genetic testing — and are increasingly seeking out CancerIQ as a solution.

"As a previvor who has lost loved ones to breast cancer, my driving purpose is to expand access to cancer risk assessment and life-saving, genetically informed prevention, treatment and survivorship care. No company does that better than CancerIQ," she said.

With her focus on strategic partnerships, Senatra will work closely with CancerIQ's provider partners to ensure they meet the moment for their patients and get ahead of cancer by improving high-risk patient identification, genetic testing uptake, patient education and long-term medical management. https://lnkd.in/e2uW8Cdd

#CancerPreventionAwarenessMonth #AheadOfCancer #PrecisionPrevention #Previvor

Jessica Hagen at MobiHealthNews, HIMSS Media recently tapped CancerIQ CEO & Co-Founder Feyi Ayodele for a Q&A on the growth of digital health: "The more we learn about the relationship between cancer and our genes and other factors as the science evolves, we should be able to act on that knowledge."

"CancerIQ is a company on a mission to really expand access to the latest innovations in cancer prevention, early detection and treatment. We do that by making sure we're really fully integrating genomic medicine into routine care... We’re truly in the business of interpreting this information, making sure it's getting to patients and is truly in their hands, so that all patient populations can really act on the information, versus just getting tested on its own."

https://bit.ly/47SdNi9 #HIMSS #aheadofcancer #digitalhealth #precisonprevention

KLAS Research interviewed 52 healthcare professionals, and I’m surprised, honored and excited to learn that CancerIQ was named in the final report among the most promising emerging health IT companies of 2024.

This unexpected recognition shows that healthcare leaders recognize that they can't achieve their goals with an EHR alone, and are increasingly seeking out CancerIQ as a solution.

To the anonymous team that heard about CancerIQ and dropped our name to the researcher team at KLAS - thanks for sharing! 

The time is now to use genetic information to get ahead of cancer, and we love that we've been recognized as best in class!

Read more about the report here: https://bit.ly/3OdKwaI

#HITvendors #HITnews #aheadofcancer #precisionprevention

What happens to cancer center volumes when many more breast cancer patients are suddenly eligible for services that are already in high demand? A much larger pool of patients now requires access to genetics given the American Society of Clinical Oncology (ASCO)'s and the Society of Surgical Oncology (SSO)'s recently expanded BRCA1/2 mutation testing recommendations for all breast cancer patients under 65 years old and select patients over age 65.

Importantly, the increased volume of genetic tests introduces a greater demand for genetic counseling, patient education and long-term medical management. As such, providers will need better tools to properly manage their patients. Learn how CancerIQ can help: https://bit.ly/3Hp9iRh

#aheadofcancer #precisionprevention #oncology

The American Cancer Society report lays bare the dire need to broadly screen for cancer predisposition due to genetic, familial, lifestyle and adherence risk, test appropriate patients for genetic mutations at scale, and dramatically increase the number of patients under personalized management. The time is now. And we, along with our incredible health system, lab and screening partners, are working as hard as we can to save lives and reduce the number of patients and families that have to endure the pain that comes along with a late-stage cancer diagnosis.

Myriad Genetics is a leading genetic testing company that offers a range of tests for hereditary cancer risk assessment, including breast cancer.

Myriad Genetics

Invitae is a company specializing in genetic testing and offers tests for hereditary cancer risk assessment, including breast cancer.

Invitae

Color Genomics is a genetic testing company that provides tests for hereditary cancer risk assessment, including breast cancer, with a focus on accessibility and affordability.

Color Genomics

CancerIQ is a healthcare technology company that uses artificial intelligence and machine learning to help healthcare providers identify patients at high risk of developing cancer, particularly breast cancer, and provide personalized recommendations for prevention and early detection.

news impact assignment basic	general	May 3, 2024 7:41 PM	bdee7e4b
public peers	general	May 3, 2024 7:41 PM	913d6662
news daily refresh	general
news processing daily refresh	general
news impact assignment daily	general
news processing basic	general	May 3, 2024 7:41 PM	8312a02b
company summary	general
signals	general
crunchbase trigger	general	Nov 27, 2024 12:50 PM	8f8b0844
crunchbase profile	general
li profile	general	May 3, 2024 7:41 PM	71827477
translate crunchbase fundingrounds	general
peers	general
news basic	general	May 3, 2024 7:41 PM	01a1a51b
bundesanzeiger	filings
financials download nd	financials
private financials	financials

COM:CANCERIQ

CancerIQ